Search results for "time factor"

showing 10 items of 3219 documents

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

2017

Background Our aim was to evaluate the association between the soluble form of neprilysin ( sNEP ) levels and long‐term all‐cause, cardiovascular, and acute heart failure ( AHF ) recurrent admissions in an ambulatory cohort of patients with heart failure. sNEP has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. Methods and Results We measured sNEP levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all‐cause, cardiovascular, and AHF hospitalizations during…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_class030204 cardiovascular system & hematologyPatient Readmissionneprilysin03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInterquartile rangeCause of DeathInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineAgedOriginal ResearchAged 80 and overHeart Failurereadmissionbusiness.industryIncidenceMiddle AgedPrognosismedicine.diseasePeptide FragmentsConfidence intervalUp-RegulationQuartileSpainHeart failureCohortAmbulatoryCardiologyBiomarker (medicine)FemaleNeprilysinCardiology and Cardiovascular MedicinebusinessReadmissionBiomarkers
researchProduct

Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors

1996

Abstract Similarly to clozapine, a clozapine metabolite, N -desmethylclozapine, but not clozapine N -oxide, antagonized brain γ-aminobutyric acid type A (GABA A ) receptors at high micromolar concentrations. However, daily subcutaneous injections of clozapine (10 and 25 mg/kg) and haloperidol (0.5 mg/kg) for 14 days failed to alter the modulation by GABA of rat cerebrocortical and cerebellar benzodiazepine ([ 3 H]flunitrazepam) or convulsant ( t -[ 35 S]bicyclophosphorothionate) binding sites of the GABA A receptor. The results thus suggest that the GABA A receptor antagonism exerted by chronic in vivo clozapine treatment is weak as compared to this treatment's actions on certain monoamine …

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classDrug Evaluation PreclinicalDesmethylclozapineIn Vitro TechniquesPharmacologyBiologyGABA AntagonistsRats Sprague-Dawleychemistry.chemical_compoundInternal medicinemedicineHaloperidolAnimalsGABA-A Receptor AntagonistsReceptorClozapineClozapinePharmacologyBenzodiazepineGABAA receptorBrainRatsLogistic ModelsEndocrinologychemistryConvulsantHaloperidolFlunitrazepamAntipsychotic Agentsmedicine.drugEuropean Journal of Pharmacology
researchProduct

Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline …

2005

OBJECTIVES: The aim of this study was to evaluate the effect of a new treatment for refractory congestive heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station. BACKGROUND: The study was aimed at evaluating the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) in refractory CHF patients. METHODS: A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were enrolled. They had to have an ejection fraction <35%, serum creatinine <2 mg/dl, blood urea nitrogen <60 mg/dl, a reduced urinary volume, and a low natriuresis (<500 ml/24 h and <60 mEq/24 h, respectively). Pati…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classNatriuresisDouble-Blind MethodFurosemideHeart rateNatriuretic Peptide BrainNatriuretic peptidemedicineElectric ImpedanceHumansDiureticsBlood urea nitrogenAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionDose-Response Relationship Drugbusiness.industryBioelectrical ImpedanceBrain Natriuretic peptideFurosemideMiddle Agedmedicine.diseaseBrain natriuretic peptideSurgeryHeart failureAnesthesiaDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in th…

2009

A number of in vitro and in vivo studies using selective agonists have indicated a neuroprotective role for group-II metabotropic glutamate (mGlu2/3) receptors in various models of neuronal injury. Although an interplay among neurotrophic factors and mGlu2/3 receptors signalling system has been suggested as possible mechanism involved on neuroprotection, at present poor information are available concerning the in vivo regulation by mGlu2/3 receptors activation of specific neurotrophic factors. By using in situ hybridization and western blotting methods the aim of present study was to analyse the potential regulatory role of selective mGluR2/3 agonist LY379268 treatment on brain derived neur…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classTropomyosin receptor kinase BBiologyReceptors Metabotropic GlutamateHippocampusSettore BIO/09 - FisiologiaMiceNeurotrophic factorsInternal medicineExcitatory Amino Acid AgonistsmedicineAnimalsRNA MessengerAmino Acidsneurotrophic factorNeuronsBrain-derived neurotrophic factorDose-Response Relationship DrughippocampuBrain-Derived Neurotrophic FactorGeneral NeuroscienceGlutamate receptorBrainLY379268Bridged Bicyclo Compounds HeterocyclicReceptor antagonistUp-RegulationMice Inbred C57BLMetabotropic receptorEndocrinologyBDNFXanthenesMetabotropic glutamate receptorcerebral cortexMetabotropic glutamate receptor 2Excitatory Amino Acid AntagonistsmGlu2/3 receptor
researchProduct

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treate…

2021

Background We assessed the impact of preprocedural plasma levels of MRproANP (midregional N‐terminal pro–atrial natriuretic peptide) and sST2 (soluble suppression of tumorigenicity 2) on recurrence of atrial fibrillation (AF) at 1 year after catheter ablation of AF. Methods and Results This was a prospective, multicenter, observational study including patients undergoing catheter ablation of AF. MRproANP and sST2 were measured in a peripheral venous blood preprocedure, and MRproANP was assessed in the right and left atrial blood during ablation. The primary end point was recurrent AF between 3 and 12 months postablation, defined as a documented (>30 seconds) episode of AF, flutter, or a…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentBiorhythmCatheter ablation030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineHeart RatePredictive Value of TestsRecurrenceRisk FactorsInternal medicinecatheter ablationAtrial FibrillationmedicineNatriuretic peptideHumansIn patientArrhythmia and Electrophysiology030212 general & internal medicineHeart AtriaProspective StudiesOriginal ResearchAgedsST2business.industryMRproANPbiomarkersAtrial fibrillationPlasma levelsMiddle Agedmedicine.diseaseInterleukin-1 Receptor-Like 1 ProteinUp-RegulationHeart RhythmTreatment OutcomePro atrial natriuretic peptideCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCatheter Ablation and Implantable Cardioverter-DefibrillatorAtrial Natriuretic FactorJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005–201…

2018

International audience; Background - Women show greater mortality after acute myocardial infarction. We decided to investigate whether gender affects delays and impacts in-hospital mortality in a large population.Methods and results - We performed a patient-level analysis of 7 French MI registries from different regions from January 2005 to December 2012. All patients with acute STEMI were included within 12 h from symptom onset and a first medical contact with a mobile intensive care unit an emergency department of a hospital with percutaneous coronary intervention facility. Primary study outcomes were STEMI, patient and system, delays. Secondary outcome was in-hospital mortality. 16,733 p…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyClinical researchSTEMIElectrocardiography03 medical and health sciencesSex Factors0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsGender issuesmedicineHumansST segmentRegistries030212 general & internal medicineMyocardial infarctionSex DistributionSurvival rateAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionRetrospective cohort studyEmergency departmentMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthSurvival RateClinical researchEmergency medicineST Elevation Myocardial InfarctionFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: results from the P…

2019

Background Elderly patients (≥75 years old) with non-ST-segment elevation myocardial infarction (NSTEMI) represent a large subgroup of all cases. They are rarely included in randomized trials because of comorbidities and concerns about complications. Furthermore, invasive treatments are used less frequently in this patient group. The aim of this study was to analyze trends in invasive procedures and outcomes in elderly patients with NSTEMI from 2005 to 2014. Patients and methods We analyzed 68 978 elderly patients with NSTEMI enrolled in the prospective, nationwide Polish Registry of Acute Coronary Syndromes from 2005 to 2014. Results Elderly patients accounted for 34.9% of all patients wit…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionSex FactorsRandomized controlled triallawPredictive Value of TestsRisk FactorsInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionHospital MortalityRegistriesHealthcare DisparitiesNon-ST Elevated Myocardial InfarctionAgedbusiness.industryAge FactorsPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseaseConfidence intervalStandardized mortality ratioTreatment OutcomePredictive value of testsRelative riskFemalePolandCardiology and Cardiovascular MedicinebusinessCoronary artery disease
researchProduct

Initial Clinical Experience Using the Low-Profile Altura Endograft System With Double D-Shaped Proximal Stents for Endovascular Aneurysm Repair.

2018

Purpose: To report the initial clinical results of endovascular aneurysm repair (EVAR) using the low-profile (14-F) Altura Endograft System, which features a double “D-shaped” stent design with suprarenal fixation and modular iliac components that are deployed from distal to proximal. Methods: From 2011 to 2015, 90 patients (mean age 72.8±8.3 years; 79 men) with abdominal aortic aneurysm (AAA; mean diameter 53.8±5.7 mm) were treated at 10 clinical sites in 2 prospective, controlled clinical studies using the Altura endograft. Outcomes evaluated included mortality, major adverse events (MAEs: all-cause death, stroke, paraplegia, myocardial infarction, respiratory failure, bowel ischemia, an…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyProsthesis DesignEndovascular aneurysm repairRisk Assessment03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicinePostoperative ComplicationsRisk FactorsmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionAdverse effectStrokeAgedAged 80 and overbusiness.industryPatient SelectionEndovascular ProceduresMiddle Agedmedicine.diseaseThrombosisAbdominal aortic aneurysmSurgeryBlood Vessel ProsthesisProsthesis FailureTreatment OutcomeRespiratory failureSurgeryFemaleStentsCardiology and Cardiovascular MedicineParaplegiabusinessAortic Aneurysm AbdominalJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Immunoglobulin G4-Related Aortitis and Severe Aortic Valve Stenosis Treated With Transcatheter Aortic Valve Replacement and Immunosuppression.

2021

Abstract IgG4-related disease is an immune-mediated fibro-inflammatory disorder with multisystemic involvement. Aortitis and peri-aortitis are the most common cardiovascular manifestations of the disease. We present the case of a 65-year-old man with symptomatic severe aortic stenosis and concomitant IgG4 aortitis. The diagnosis was confirmed by IgG4 serum levels, positive positron emission computed tomography (PET-CT) scans, and pathology from mediastinal dissection. Surgical aortic valve replacement (SAVR) was unfeasible owing to extensive mediastinal fibrosis, and transcatheter aortic valve replacement (TAVR) was successfully performed. As ascending aorta access for SAVR in IgG4 aortitis…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAorta ThoracicSeverity of Illness IndexTranscatheter Aortic Valve ReplacementMediastinal fibrosisAortic valve replacementValve replacementFibrosisInternal medicinemedicine.arteryPositron Emission Tomography Computed Tomographyparasitic diseasesAscending aortaMedicineHumansAortitisAgedAortitisbusiness.industryAortic Valve Stenosismedicine.diseaseStenosisAortic valve stenosisAortic ValveHeart Valve ProsthesisImmunoglobulin GCardiologyImmunoglobulin G4-Related Diseasemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesThe Canadian journal of cardiology
researchProduct